Advanced Search

 

Study ID Status Title Patient Level Data
208133/178 Completed A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older. Study Listed on ClinicalStudyDataRequest.com
208136/006 Completed A phase II, open, randomized, multicentre study evaluating in healthy children 12-24 months of age, the safety and immunogenicity of GlaxoSmithKline Biologicals' combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA), compared to GlaxoSmithKline Biologicals' Varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/007 Completed Study to assess consistency of 3 production lots of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Biologicals’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life Study Listed on ClinicalStudyDataRequest.com
208136/013 Completed Study to assess immunogenicity and safety of one dose of GSK Biologicals’ live attenuated MMRV vaccine, co-administered with a booster dose of the GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine Study Listed on ClinicalStudyDataRequest.com
208136/014 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella Study Listed on ClinicalStudyDataRequest.com
208136/016 Completed Study to assess immunogenicity and safety of two lots of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Biologicals’ measles-mumps-rubella vaccine as control group Study Listed on ClinicalStudyDataRequest.com
208136/017 Completed Study to assess immunogenicity, reactogenicity and safety of a second dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age Study Listed on ClinicalStudyDataRequest.com
208136/018 Completed Study to evaluate immunogenicity and safety of GSK Biologicals’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Biologicals’ Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/019 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/022 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Biologicals' measles-mumps-rubella vaccine and varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/038 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/039 Completed Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®. Study Listed on ClinicalStudyDataRequest.com
208136/040 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208136/041 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208139/053 Completed Open, multicentric, post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine (TRITANRIX-HB) injected in healthy infants according to theprescribing information Study Listed on ClinicalStudyDataRequest.com
208139/054 Completed An open randomised study in healthy infants vaccinated at birth with Engerix™-B (10µg) to evaluate the immunogenicity and the reactogenicity of the following GlaxoSmithKline (GSK) Biologicals’ vaccines: 1) combined DTP-HB vaccine (10µg HBsAg), 2) combined DTP-HB vaccine (5µg HBsAg), 3) simultaneous administration of Engerix™-B (10µg) vaccine in right thigh and whole-cell DTP vaccine in left thigh, when administered at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
208141/017 Completed Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease Study Listed on ClinicalStudyDataRequest.com
208141/037 Completed Open study to further evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/038 Completed Open study to further evaluate the safety, reactogenicity, and immunogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ Phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/040 Completed A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years. Study Listed on ClinicalStudyDataRequest.com
208141/041 Completed Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule. Study Listed on ClinicalStudyDataRequest.com
208141/042 Completed A Phase III, double-blind, randomized, study to compare: 1) the immunogenicity and safety of 3 commercial scale consistency lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate vaccine in healthy HSV-1 and -2 seronegative (HSV 1-/2-) female subjects aged 10 – 17 years, and 2) vaccine immunogenicity in healthy HSV 1-/2- females aged 10 – 17 years with healthy HSV 1-/2- adult females Study Listed on ClinicalStudyDataRequest.com
208355/123 Completed A phase III, open, multicenter study of the safety and immunogenicity of a booster dose of SmithKline Beecham Biologicals’ Diphtheria and Tetanus toxoids and acellular Pertussis (DTaP) vaccine (Infanrix™) and Pasteur Mérieux’s Haemophilus influenzae type b (Hib) conjugate vaccine (OmniHIB®) when administered intramuscularly as separate injections between 12 and 18 months of age following primary immunization at 2 months, 4 months, and 6 months of age in study DTPa-HBV-IPV-027 (217744/027) Study Listed on ClinicalStudyDataRequest.com
208355/124 Completed An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa vaccine or GSK Biologicals’ DTPa vaccine or Chiron Behring’s Td vaccine + either Pasteur Merieux’s Pa vaccine or GSK Biologicals’ pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118) Study Listed on ClinicalStudyDataRequest.com
208355/125 Completed A phase III, open, multicenter study of the safety of Infanrix® when administered as a booster dose at 15 to 18 months of age following primary immunization in studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.